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Molecular dynamicsFollowing an increase in detection of enterovirus 68 (EV68) in community surveillance of respiratory infec-
tions in The Netherlands in 2010, epidemiological and virological analyses were performed to investigate the
possible public health impact of EV68 infections. We retrospectively tested specimens collected from acute
respiratory infections surveillance and through three children cohort studies conducted in The Netherlands
from 1994 through 2010. A total of 71 of 13,310 (0.5%) specimens were positive for EV68, of which 67
(94%) were from symptomatic persons. Twenty-four (34%) of the EV68 positive specimens were collected
during 2010. EV68-positive patients with respiratory symptoms showed signiﬁcantly more dyspnea, cough
and bronchitis than EV68-negative patients with respiratory symptoms. Phylogenetic analysis showed an
increased VP1 gene diversity in 2010, suggesting that the increased number of EV68 detections in 2010
reﬂects a real epidemic. Clinical laboratories should consider enterovirus diagnostics in the differential
diagnosis of patients presenting with respiratory symptoms.
© 2011 Elsevier Inc. All rights reserved.Introduction
Viruses of the family Picornaviridae genus Enterovirus cause a wide
spectrum of disease in humans including upper and lower respiratory
tract disease, pleurodynia, gastro-enteritis, hand-foot-and-mouth dis-
ease, herpangina, exanthema, myocarditis, pericarditis, paralysis,se Control (CIb), Laboratory for
titute for Public Health and the
he Netherlands. Fax: +31 30
abine.van.der.sanden@rivm.nl
ders),
rez), l.bont@umcutrecht.nl
, pieter.overduin@rivm.nl
usic@rivm.nl (E. Jusic),
),
nivel.nl (G.A. Donker),
rights reserved.aseptic meningitis and generalized disease of the newborn
(Khetsuriani et al., 2006; Rotbart, 1995; Zaoutis and Klein, 1998).
Human enterovirus species D type 68 (EV68) has been detected almost
exclusively in respiratory tract specimens and has been associated with
respiratory disease since its discovery in 1962 (Khetsuriani et al., 2006;
Oberste et al., 2004; Schieble et al., 1967). When ﬁrst described, EV68
was found to be relatively acid resistant and was distinguished from
the acid sensitive human rhinovirus type 87 (HRV87) on this basis
(Kapikian et al., 1971; Schieble et al., 1967). Recently, HRV87 was
reclassiﬁed as EV68 based on phylogenetic analysis and cross-
neutralization, and several laboratories have conﬁrmed acid sensitivity
of EV68 (Blomqvist et al., 2002; Ishiko et al., 2002; Savolainen et al.,
2002). Distinguishing between rhinovirus and enterovirus by the acid
sensitivity of isolates is therefore not appropriate for EV68.
In the USA, EV68 was detected only sporadically from 1970
through 2005 (Khetsuriani et al., 2006). EV68 infections have since
been reported more frequently, but almost always associated with
50 A. Meijer et al. / Virology 423 (2012) 49–57respiratory disease (de Almeida et al., 2010; Imamura et al., 2011;
Kaida et al., 2011; Petitjean-Lecherbonnier et al., 2011; Piralla et al.,
2011; Rahamat-Langendoen et al., 2011; Renwick et al., 2007;
Savolainen-Kopra et al., 2009; She et al., 2010; Smura et al., 2010;
Tokarz et al., 2011; Wang et al., 2010). Information on clinical sever-
ity of EV68 infections is limited, but recent studies show the associa-
tion of EV68 infection with severe respiratory disease requiring
hospitalization, disease of the central nervous system, and death
following pneumonia in two patients and following disease of the
central nervous system in one patient (Imamura et al., 2011; Kreuter
et al., 2011; Petitjean-Lecherbonnier et al., 2011; Piralla et al., 2011;
Rahamat-Langendoen et al., 2011).
In the Dutch enterovirus surveillance to document the absence of
poliovirus circulation, EV68 has not been detected since 1963 (van
der Sanden et al., manuscript in preparation). This is likely because
of the surveillance design, which focuses on stool testing and there-
fore would not detect most respiratory pathogens. Furthermore,
patients with respiratory disease are not routinely tested for en-
teroviruses, and EV68 might be misidentiﬁed as rhinovirus because
of its acid sensitivity and reactivity in certain presumed rhinovirus
speciﬁc PCR assays (de Almeida et al., 2010; CDC, 2011; Jaramillo-
Gutierrez et al., manuscript in preparation). For these reasons, cases
of EV68 infection may have gone unnoticed in The Netherlands and
elsewhere. Furthermore, the 100% seroprevalence recently described
in pregnant women in Finland (Smura et al., 2010) suggests that
EV68 infections may be common.
In The Netherlands, we noticed an increased detection of enterovi-
ruses and rhinoviruses from the sentinel general practice (GP) net-
work surveillance for respiratory illness from early September 2010,
which coincided with an increased incidence of inﬂuenza-like illness
(ILI) (Fig. 1). As the summer wave of rhinovirus infections was not ac-
companied with increased incidence of ILI and the enteroviruses were
almost exclusively EV68, we started to investigate the characteristics
of EV68 viruses and associated respiratory illness. To this end, we ret-
rospectively screened our biobank of historical upper respiratory tract
specimens, collected through the acute respiratory infections surveil-
lance and through three children cohort studies, for the presence of
EV68 and we analyzed associated epidemiological and clinical data.
In addition, we studied the genetic diversity and population dynamics
of EV68 using partial VP1 gene sequences to assess whether the in-
crease in number of EV68 detections reﬂected a real epidemic or
was the result of a surveillance artifact.N
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Fig. 1. Weekly ILI consultation rates and absolute number of total enterovirus (includ-
ing EV68) (in blue) and EV68 detections (in red) for the GP sentinel surveillance year
2010, plotted by week of specimen collection.Results
Rates of enterovirus 68 detection
The rate of EV68 detections in biobanked specimens from patients
with respiratory symptoms collected as part of the GP surveillance
from 1994 through 2010, varied between seasons (mean 18%, median
14%, range 0–69%; Table 1). In total, 240 (2.4%) of the 9979 specimens
analyzed were enterovirus positive, and of these 57 (24%) were char-
acterized as EV68. Between 2000 and 2004 respiratory specimens
were also collected from 567 control persons without respiratory
symptoms as part of a case–control study as described previously
(van Gageldonk-Lafeber et al., 2005). Only one of these control per-
sons was positive for EV68. In the three children cohort studies
from 2004 through 2009, 76 of 2764 (2.7%) specimens analyzed con-
tained enterovirus of which 13 (17%) from a total of 12 patients were
identiﬁed as EV68 (Table 2).
Except for 2010 in which EV68 detections peaked during a 6-week
period, only sporadic cases were identiﬁed in the other years of the
surveillance (Fig. 2). However, almost all EV68 were detected in Sep-
tember through November throughout the study period and the dis-
tribution of EV68 detections across The Netherlands, including
during the peak in 2010, was not conﬁned to any particular region
(data not shown).
Clinical manifestations from GP surveillance
EV68-positive patients with acute respiratory symptoms were
compared with patients diagnosed at corresponding times with
acute respiratory symptoms due to other causes. Demographic pa-
tient characteristics, clinical symptoms and diagnosis at initial con-
sultation in the period 1996–2010 are summarized (Table 3). The
highest prevalence of EV68-positive patients was among persons
aged 50–59 years, while the highest number of EV68-negative pa-
tients was in the b10 years age group (Table 3). The male/female
ratio among EV68-positive and EV68-negative patients was 1.5 and
0.8 (χ2; p=0.001), respectively. EV68-positive patients had signiﬁ-
cantly more dyspnea, cough, and bronchitis when compared to
EV68-negative patients (Table 3). Patients with dyspnea had signiﬁ-
cantly higher incidence of bronchitis than those without dyspnea,
22.9% versus 4.5% (Fisher's exact; pb0.0007). Similarly, patients
with cough had signiﬁcantly more bronchitis than patients without
cough, 8.7% versus 0.5% (Fisher's exact; pb0.00001). EV68-positive
patients had signiﬁcantly less fever, malaise, myalgia and diarrhea
than EV68-negative patients (Table 3). Considering the epidemic
year 2010 only, similar results were obtained (data not shown).
After stratiﬁcation for the diagnosis “ILI” and “another acute respi-
ratory infection (ARI)”, in both groups EV68-positive patients had sig-
niﬁcantly less fever and more dyspnea than EV68-negative patients
(χ2; pb0.02 in all comparisons). In addition, EV68-positive ARI pa-
tients had signiﬁcantly more bronchitis than EV68-negative ARI pa-
tients (χ2; p=0.0002). After stratiﬁcation for EV68 and rhinovirus
infection, EV68-infected patients also had signiﬁcantly more dyspnea
and bronchitis than rhinovirus-infected patients (χ2; p≤0.002 in all
comparisons).
Follow-up questionnaires from 14 EV68-positive and 76 EV68-
negative patients with an acute respiratory infection from the 2010
epidemic period were available for analyses (Table 4). There were
no signiﬁcant differences in follow-up between EV68-positive and
EV68-negative patients for any of the conditions analyzed.
Clinical manifestations from children cohort studies
In the three children cohort studies 9 of 12 EV68-positive persons
showed mild respiratory symptoms, with cough being the most com-
mon symptom in 7 out of 9 cases (Table 2). None of the ill persons
Table 1
Enterovirus and EV68 detections and success rate of VP1 sequencing of sentinel GP surveillance specimens from clinically ill patients, by year of specimen collection.
Year Specimens tested
No.
Enterovirus-positive
No. (% of specimens tested)
VP1 sequence obtaineda
No.
Sequencing success
%
EV68
No.
Proportion EV68 among enteroviruses
% (95% CI)b
1994c 99 5 (5.0) 5 100 0 0 (0–43)
1995 847 6 (0.7) 4 67 0 0 (0–39)
1996 354 7 (2.0) 4 57 1 14 (3–51)
1997 490 18 (3.7) 7 39 1 6 (1–26)
1998 465 14 (3.0) 7 50 1 7 (1–31)
1999 365 6 (1.6) 3 50 1 17 (3–56)
2000 278 7 (2.5) 5 71 1 14 (3–51)
2001 210 5 (2.4) 4 80 2 40 (12–77)
2002 207 5 (2.4) 2 40 0 0 (0–43)
2003 295 10 (3.4) 2 20 2 20 (6–51)
2004d 201 5 (2.5) 0 0 0 0 (0–43)
2005d 308 1 (0.3) 1 100 0 0 (0–79)
2006 610 28 (4.6) 18 64 5 18 (8–36)
2007 812 18 (2.2) 16 89 4 22 (9–45)
2008 1054 15 (1.4) 15 100 9 60 (36–89)
2009 2340 55 (2.4) 48 87 6 11 (5–22)
2010e 1044 35 (3.4) 34 97 24f 69 (52–81)
Total 9979 240 (2.4) 175 73 57 24 (19–30)
a Partial VP1 sequences, nucleotides 132 through 471 relative to the VP1 gene of the Fermon strain of EV68 (GenBank ID: AY426531) were directly obtained from the clinical
specimen to avoid sequencing of nucleic acid and amino acid substitutions possibly induced by virus isolation in tissue culture.
b Determined using Willson's estimate of the 95% conﬁdence interval (CI) of proportions in the statistical software package WINPEPI version 10.9 (Abramson, 2011).
c Start at week 43.
d No PCR used during the season 2004–2005, only virus isolation.
e Through week 49.
f In 1 specimen EV68 was identiﬁed by sequencing of the 5′ noncoding region diagnostic RT-PCR product only.
51A. Meijer et al. / Virology 423 (2012) 49–57developed complications and respiratory symptoms resolved within
4 weeks following detection of EV68. The remaining 3 EV68-positive
persons were sampled at the time when they did not show respiratory
symptoms (Table 2).
Phylogenetic analysis and evolutionary dynamics of enterovirus 68
To gain insight in the molecular epidemiology of EV68 and to as-
sess whether the increase in the number of EV68 detections in 2010
reﬂected a real epidemic, partial VP1 sequences from The Netherlands
were analyzed along with available EV68 VP1 sequences from Gen-
Bank using Bayesian relaxed molecular clock methods that allow the
evolutionary rate to vary among branches on the tree. Phylogenetic
analysis revealed that EV68 strains from several parts of the world
(US, Finland, France, The Netherlands, and Japan) formed three major
evolutionary lineages, each supported by 100% posterior probabilities
(Fig. 3).
Viruses belonging to these clusters were distinguishable by a cluster
speciﬁc signature of amino acid substitutions relative to the FermonTable 2
Enterovirus and EV68 detections with patient characteristics in 3 children cohorts in the pe
Studya Patients
No.
Specimens
No.
Specimens/patient
Median; range
Enterovirus
No. (no. patients)
EV68
No. (no. pa
WHISTLER 170 1456 11; 1–19 16 (14) 1 (1, F)c
CF (patients) 21 356 18; 1–23 13 (7) 5 (4, 3 M,
CF (controls) 19 303 17; 6–20 12 (9) 1 (1, F)e
NAF 255 649 2; 1–9 35 (30) 6 (6, 6 M)
All combined 2764 76 (60) 13 (12)d
a WHISTLER = Wheezing Illnesses Study Leidsche Rijn study, CF = cystic ﬁbrosis case–c
b Age in months (mo) or years (y) plus months (mo).
c EV68 identiﬁcation by sequencing of the 5′ noncoding region diagnostic RT-PCR produ
d One patient was sampled on 2 subsequent days and both specimens contained identica
e Twin sister without symptoms who was found positive for EV68 one week before the tstrain (Fig. 4). Dutch strains from 2010 primarily belonged to cluster 3
together with Japanese strains (5 of 39 available sequences) from
2010. The main Dutch variant circulating in the community in 2009,
which was only detected in hospitalized patients in 2010 in The
Netherlands, formed cluster 1 with Japanese strains (7/39) from 2010.
Only 1 Dutch strain from 2009 was in cluster 2 with the majority of
Japanese strains (27/39) from 2010.
A Bayesian skyline plot (BSP) (Drummond and Rambaut, 2007) of
the partial VP1 sequence data was calculated to visualize temporal
changes in relative viral genetic diversity of the Dutch EV68 strains
using Bayesian coalescent approach (Drummond et al., 2006). The
BSP revealed relatively constant viral diversity from the ﬁrst EV68
detection in 1996 through approximately 2000 after which there is a
slight increase in relative genetic diversity that likely reﬂects increased
circulation (Fig. 2). From2003 onwards viral diversity decreased slowly,
until a sharp rise is observed in 2010, reﬂecting the increased detection
of EV68 in that period (Fig. 2). The observed dynamics could not be
explained by bias due to model selection or ﬂuctuations in sampling
density through time, as trends were similar when different modelriod 2004–2009.
tients, gender) Age patient at sampling (range)b Symptoms
0.8 mo None
1 F)d 7.7 mo–3 y plus 7.8 mo 3/4 Cough
1/4 Rhinorrhea
1/4 None
7.6 mo None
1.8 mo–9.7 mo 6/6 Common cold symptoms:
acute onset, fever and rhinorrhea
4/6 Cough
1/6 Otalgia and ororrhea
1/6 Wheezing (happy wheezer)
ontrol study, NAF = Netherlands amniotic ﬂuid study.
ct only.
l EV68 VP1 sequences.
win brother with cystic ﬁbrosis became positive for EV68 with respiratory symptoms.
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
R
el
at
iv
e 
ge
ne
tic
 d
ive
rs
ity
N
um
be
r o
f E
V6
8 
de
te
ct
io
ns
Time (week and year)
Children cohorts
Sentinel surveillance
8
7
6
5
4
3
2
1
0
1.0E+05
1.0E+04
1.0E+03
1.0E+02
Fig. 2. Number of EV68 detections from the GP sentinel surveillance (in red) and children cohorts (in green) plotted by week and year of specimen collection. Superimposed on this
graph is the Bayesian skyline plot (uninterrupted line) with 95% highest posterior density (HPD) intervals (dashed lines; a Bayesian analog to a conﬁdence interval), determined
using Dutch EV68 partial VP1 sequences with the full date of specimen collection included. It shows the relative measure for genetic diversity through time with the values plotted
on the secondary y-axis.
52 A. Meijer et al. / Virology 423 (2012) 49–57parameters were used in the BSP reconstruction. Down sampling of
VP1 sequences from 2010, to correct for potential bias from increased
sampling density during the EV68 epidemic, also revealed similar pat-
terns of viral diversity (data not shown).
Amino acid sequence analysis
To identify potential viral factors in the increased incidence of
EV68, we characterized all available partial VP1 gene sequences for
amino acid changes relative to the EV68 Fermon reference strain
from 1962, following phylogenetic analysis of all unique amino acid
signature sequences in the dataset (Fig. 4). The majority of amino
acid substitutions were found at residues 90–99, 140–145, 148, and
152, relative to the EV68 Fermon reference strain from 1962
(Fig. 4). In addition, an amino acid deletion occurred at position 140
in all viruses belonging to cluster 3 (Fig. 4). On the basis of the previ-
ously published crystal structure and alignment of VP1 sequences
with those of other enterovirus serotypes, these regions are predicted
to be located in the putative immunogenic BC loop and DE loop, both
reported to be associated with infectious properties of enterovirus
particles (Chambon et al., 2004; Nix et al., 2006; Norder et al., 2003;
Oberste et al., 1999). These loops are exposed on the outside of the
virus in the folded VP1 capsid protein. Four of the 5 remaining ﬁxated
substitutions were located in the vicinity of the BC and DE loops (res-
idue positions 76, 84, 110, and 131).
Discussion
We have demonstrated the presence of EV68 in The Netherlands
since 1996 among patients with acute upper respiratory tract disease,
and provided evidence for annual circulation during September
through November. As we tested the specimens using consistent di-
agnostic methodologies with the capability to detect EV68 (Table 5),
these results likely give a true relative estimate of the extent of EV68
circulation in The Netherlands. Although the overall prevalence of en-
teroviruses appears low – 0.3% to 5.0% of patients with ILI or ARI per
year from the community surveillance – compared to other respiratory
cohorts (e.g. reviewed in Andréoletti et al., 2009), the data conﬁrm
that there was a large community-wide outbreak in 2010. A similar
observation was made through community surveillance of patientspresenting with ILI in the New York City area, with a 3% annual
prevalence of enteroviruses, where EV68 peaked in September 2009
(Tokarz et al., 2011). The age distribution of EV68-infected persons
in the current study was different from the typical age distribu-
tion for enteroviruses that affect younger age groups (Khetsuriani
et al., 2006; Rotbart, 1995; Zaoutis and Klein, 1998). In the USA,
EV68 infections most commonly occurred in children aged 1–4 years
(n=26), although 25% of EV68-infected persons were aged ≥20 years
(Khetsuriani et al., 2006). Male predominance among EV68-infected
persons in our study was similar to that for other enterovirus infec-
tions (Khetsuriani et al., 2006; Rotbart, 1995).
Recent reports of EV68 detection are mainly from studies target-
ing patients with severe respiratory disease requiring hospitalization
(Imamura et al., 2011; Petitjean-Lecherbonnier et al., 2011; Piralla
et al., 2011; Rahamat-Langendoen et al., 2011). Combined, our data
show that EV68 infections in the community are more often associ-
ated with relatively severe acute respiratory disease, i.e. dyspnea
and bronchitis, but do not more often lead to complications com-
pared with patients diagnosed with ILI or another ARI because of
other causes. As EV68 was also sporadically detected in respiratory
specimens of asymptomatic persons, we conclude that the spec-
trum of clinical disease associated with EV68 infection ranges from
symptomless to severe respiratory disease requiring hospitalization,
with some cases proving fatal. Next steps in the investigation of
the clinical presentation of EV68 infection should include studies
on the pathogenesis and host factors related to a severe outcome
of EV68 infection.
The public health importance of EV68 infections as measured by
ILI consultation rate was low, with about 30 ILI cases/100,000 popula-
tion/week at the peak of EV68 detections in 2010. This is well below
the epidemic threshold of 51 ILI cases/100,000 population/week for
inﬂuenza in The Netherlands (Donker, 2011). However, of all EV68
patients only 44% were clinically diagnosed with ILI (Table 3) and
therefore GP ILI consultation rates likely underestimate the public
health importance of EV68 infections. Furthermore, our study was
limited to patients with acute upper respiratory infections. Therefore,
further investigation into the true public health impact of EV68 infec-
tions is needed.
The observed seasonality of EV68 detections to the autumn in
our study was similar to that of EV68 described for Caen in France,
Table 3
Age distribution and clinical symptoms and diagnosis of sentinel GP surveillance pa-
tients with inﬂuenza-like illness or another acute respiratory infection; EV68-
negative versus EV68-positive patients 1996–2010 collected in the same week.
Characteristic EV68-negative
patients
No.=833
EV68-positive
patients
No.=57
χ2
p-valueb
No.a % No.a %
Age group
b10 190 22.81 8 14.04 0.1233
10–19 125 15.01 9 15.79 0.8729
20–29 108 12.97 2 3.51 0.0358
30–39 121 14.53 6 10.53 0.4036
40–49 116 13.93 10 17.54 0.4484
50–59 80 9.60 15 26.32 b0.0001
60–69 54 6.48 4 7.02 0.8742
70–79 28 3.36 2 3.51 0.9524
80–89 9 1.08 1 1.75 0.6405
>89 1 0.12 0 0 0.7935
Clinical symptoms
Acute 630 82.46 44 84.62 0.6917
Fever 564 68.61 34 42.11 b0.0001
Malaise 498 60.58 34 42.11 0.006
Headache 312 38.28 14 25.45 0.0571
Myalgia 381 46.35 17 29.82 0.0154
Sore throat 441 53.65 27 47.37 0.358
Cough 622 75.67 50 87.72 0.0381
Dyspneac 22 10.95 11 36.67 0.0002
Rhinorrhea 320 38.93 20 35.09 0.5647
Diarrhea 56 6.87 0 0 0.0464
Clinical diagnosis
ARId 331 40.27 32 56.14 0.0186
Common cold 125 15.21 13 22.81 0.272
Sinusitis 29 3.53 2 3.51 0.9939
Otitis media 14 1.70 0 0 0.3206
Pharyngitis 75 9.12 5 8.77 0.9288
Tonsillitis 25 3.04 0 0 0.1816
Laryngitis 13 1.58 2 3.51 0.2773
Tracheitis 11 1.34 2 3.51 0.1892
Bronchitis 46 5.67 13 23.21 b0.0001
Bronchiolitis 4 0.50 0 0 0.607
Pneumonia 15 1.82 2 3.51 0.372
a Numbers in strata do not add up to the total number of EV68-negative and EV68-
positive patients because of missing or unknown values. One patient can have 1 or
more clinical symptom(s).
b Boldface indicates signiﬁcant result.
c Dyspnea was not included on the swab form from week 40/2000 through week
47/2009.
d The clinical diagnosis is inﬂuenza like illness (ILI) or another acute respiratory
infection (ARI). In case of ARI, the speciﬁc diagnosis is reported in the table.
Table 4
Follow-up analysis of patients in 4 weeks post onset of disease; EV68-negative versus
EV68-positive patients in weeks 35–40, 2010.
Characteristica EV68-negative
patients
No.=76b
EV68-positive
patients
No.=14b
No. % No. %
Recovered
Yes 55 94.83 13 100
No 3 5.17 0 0
Repeat consultation
Yes (visit and/or by phone) 37 51.39 8 57.14
No 35 48.61 6 42.86
Death
No 68 100 12 100
Hospitalization
Yes 4 5.88 1 9.09
No 64 94.12 10 90.91
Complications
Yes 10 15.38 2 16.67
No 55 84.62 10 83.33
Underlying conditions
Yes 22 32.35 4 33.33
No 46 67.65 8 66.67
a χ2 (or if ≥50% of cells have an expected count b5 Fisher's exact test); p-value for all
variables ≥0.67.
b Numbers in strata do not add up to the total number of EV68-negative and EV68-
positive patients because of missing or unknown values.
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Lecherbonnier et al., 2011; Piralla et al., 2011), New York City in
2009 (Tokarz et al., 2011) and Japan in 2010 (Kaida et al., 2011).
It is also similar to detection of EV68 infections in camps of military
recruits in the USA and Finland during 2004–2005 (Savolainen-
Kopra et al., 2009; Wang et al., 2010), and in USA enterovirus sur-
veillance (Khetsuriani et al., 2006). The conﬁnement of circulation
of EV68 to autumn is different from the typical period of circulation
of other enteroviruses in the summer and early autumn (Rotbart,
1995; Zaoutis and Klein, 1998).
Analysis of virus population dynamics shows a clear expansion of
the population diversity in 2010. This is not likely due to sampling
bias because the GP surveillance in The Netherlands has been stable
and consistently included the capability to detect EV68 over the peri-
od of the study. In addition, the coalescence rate for the specimens
obtained in 2010 was extremely rapid, with most lineages quickly co-
alescing to a single recent common ancestor, indicating true expo-
nential growth of the virus population in that period. Reducing the
number of VP1 sequences from 2010 in the analysis did not alter
the dynamics observed, consistent with extensive simulations ofhuman inﬂuenza virus A(H3N2) demographics where demographic
dynamics were reconstructed independently of sampling heteroge-
neity (Rambaut et al., 2008).
We found that, in the late 1980s, the 1990s, and in the early 2000s,
major bifurcations occurred in the evolution of the EV68 VP1 that cor-
responded to amino acid substitutions in the putative BC and DE
loops relative to the EV68 Fermon strain. This is in line with the ﬁnd-
ing that the geometric mean titers of neutralizing antibodies against
the prototype Fermon strain (isolated in 1962) declined from 178.8
in 1983 to 88.1 in 1993 and 44.5 in 2002, as determined by a study
in Finland in pregnant women (Smura et al., 2010). In addition, a
single amino acid loss at position 84 in the BC loop of the VP1 pro-
tein of coxsackie B4 virus was shown to reduce virus neutralization
and one amino acid exchange at position 86 in the middle of the BC
loop led to the complete loss of reactivity with speciﬁc antibodies
(McPhee et al., 1994).
Although we found some interesting patterns in amino acid muta-
tions in the VP1 protein that may help to explain the biological basis
for the increase in incidence of EV68, deletions and mutations in
other parts of the genome may also change virus behavior, for in-
stance mutations in the 5′-UTR that might increase translational efﬁ-
ciency or virulence or both (Kaida et al., 2011). Full genome analysis
of a systematic sample of EV68 is therefore needed to address these
issues.
Conclusions
Our ﬁndings demonstrate circulation of EV68 during the autumn
in The Netherlands. We found that upper respiratory tract disease
was more severe in EV68-positive patients than in patients with
other respiratory tract infections sampled at corresponding times.
Phylodynamic analysis of partial VP1 sequences showed increased
genetic diversity in 2010, indicating true epidemic spread of EV68 in
2010. Amino acid variation in the putative BC and DE loops of the im-
munogenic VP1 protein suggests that antigenic drift might explain
the increase in incidence of EV68 in 2010 in The Netherlands. We
Fig. 3.Maximum clade credibility tree with 95% HPD intervals for the node times (in years; gray bars at nodes) and posterior probabilities for branching events (numbers at nodes).
The tree was inferred using partial VP1 sequences of Dutch EV68 viruses and of EV68 viruses from other regions in the world (for Japan all unique sequences included in the tree
inference) available in GenBank by March 31, 2011, and using the year of specimen collection. Strain names consist of: laboratory number for Dutch strains or GenBank accession
number|city/village or state, or unique name or number|2-letter country iso code|year of specimen collection. Dutch strains start with plain number for sentinel GP surveillance, V
or VR for children cohort studies, or E for UMCG hospital derived strains. The geographic origin of non-Dutch strains is indicated by symbols; closed triangle for US, open triangle for
Finland, closed diamond for Japan and open diamond for France. Underlined strain names indicate strains representative for the unique amino acid signature sequences that have
been used in the amino acid sequence analysis. Major recent clusters are indicated by a vertical line at the right side and numbered.
54 A. Meijer et al. / Virology 423 (2012) 49–57recommend that clinical laboratories consider enterovirus in the dif-
ferential laboratory diagnosis of patients presenting with respiratory
symptoms.
Material and methods
Sentinel surveillance
ILI incidence data and nose and throat swabs with associated
demographic and clinical data of patients with ILI or another ARI
were collected through the Dutch continuous morbidity registration
sentinel GP network as described (Donker, 2011; Pel, 1965). Respi-
ratory specimens, collected since 1994, are shipped to the National
Institute for Public Health and the Environment, The Netherlands
and PCR-based diagnostic testing and virus isolation are conductedas described (Andeweg et al., 1999). Patient data and enterovirus-
positive specimens from week 43/1994 through week 49/2010 were
included in the study.
Children cohorts
Enterovirus-positive respiratory specimens and clinical data of
EV68-positive persons of 3 young children cohort studies in The
Netherlands were included in the study (Table 2). These studies
were the Wheezing Illnesses Study Leidsche Rijn (WHISTLER) in
which infants were followed from birth through their ﬁrst year of
life in the period 2005–2008 and swabbed during episodes of respira-
tory tract infection (Katier et al., 2004; van der Zalm et al., 2011); a
cystic ﬁbrosis (CF) case–control study in which, during the 2004–2005
winter season, children were swabbed when having respiratory illness,
4310800679|BLOEMENDAAL|NL|2008 > 2010 [2]
4310600468|AMSTERDAM|NL|2006 > 2007|8|9|10 [33]
4311000742|ASSEN|NL|2010 [1]
4310700565|AMERSFOORT|NL|2007 [1]
4310700531|EINDHOVEN|NL|2007 > 2010 [3]
4300300279|HEERDE|NL|2003 [2]
AY426500|TX03|US|2003 > 2006 [2]
4300100300|EINDHOVEN|NL|2001 [3]
4310800762|VLISSINGEN|NL|2008 [1]
AB614408|Yam1946|JP|2010 [1]
AB614425|Yam2016|JP|2010  [1]
AY426491|MD021|US|2002 > 2004|6|7|8|9|10 [22]
4310600466|OIRSBEEK|NL|2006 [2]
4310902284|SGRAVENHAGE|NL|2009 [1]
AB614437|Yam2161|JP|2010 [7]
4310900947|MIDDELBURG|NL|2009 > 2010 [6]
4310901880|ALMELO|NL|2009 [1]
AY426495|TX021|US|2002 [1]
AY426496|TX022|US|2002 [1]
3009903700|ROTTERDAM|NL|1999 > 2000 [4]
3009604041|HEILOO|NL|1996 > 1997|8|9 [6]
GQ466486|A2145|FI|2005 [1]
GQ466485|A2119|FI|2004 [2]
V071|RHENEN|NL|2004 [2]
AY208116|FR|1999 [1]
EF107098|FR|1999 [1]
AY426490|NY93|US|1993 [1]
AY426489|MN89|US|1989 [1]
AY426486|CA621|US|1962 [2]
AY426488|CA623|US|1962 [1]
AY355268|Corn-strain|US|1963 [1]
AY426531|Fermon-strain|US|1962 [2]
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Fig. 4. Amino acid sequence analysis. All unique amino acid sequences of Dutch and international EV68 partial VP1 sequences available in GenBank by March 31, 2011 were
included. The left part of the ﬁgure shows the maximum likelihood consensus bootstrap tree after 1000 iterations with percentage bootstrap support for branching events
indicated at the nodes. Names of strains which are representative for unique amino acid signature sequences are followed by the subsequent years in which the signature
sequences were found, and between brackets by the frequency in which the signature sequences were found in the dataset. Clusters as identiﬁed in Fig. 3 are indicated on
the right of the tree. The right part of the ﬁgure shows the corresponding amino acid signature sequences. Numbering of amino acid residues is relative to the start of the
VP1 reading frame of the Fermon strain of EV68. Amino acids common to the Fermon strain are indicated with a dot in the alignment. The putative BC and DE loops are in-
dicated by boxes on the aligned amino acid sequences.
55A. Meijer et al. / Virology 423 (2012) 49–57and also swabbed bi-weekly independent of respiratory symptoms
(van Ewijk et al., 2008); and The Netherlands amniotic ﬂuid (NAF)
study in which children born in a secondary or a tertiary hospital from
2006 through 2009 were swabbed in their ﬁrst year of life during each
episode of respiratory disease (Houben et al., 2009). Clinical data were
collectedwith the specimens and on frequent intervals by clinical inter-
view. The local medical ethics committee approved the studies and the
parents gave written informed consent.
Enterovirus detection and EV68 identiﬁcation
In the primary diagnostic process, freshly extracted nucleic acid
was subjected to reverse transcriptase (RT)-PCR for several respirato-
ry pathogens using primers and probes targeting the 5′ noncoding re-
gion of the genome of rhinoviruses and enteroviruses (Table 5).
Block-based nested 1-step RT-PCR with probe hybridization to distin-
guish enteroviruses from rhinoviruses was performed as described
(Andeweg et al., 1999; Kämmerer et al., 1994) (Table 5). Similar
primers were subsequently used in a 2-step real-time RT-PCR assay
with probes to distinguish enteroviruses from rhinoviruses (Table 5).
A 2-step real-time RT-PCR for enteroviruses (Noordhoek et al., 2008)
was used for further conﬁrmation of enterovirus detection (Table 5).
Combined historical results of RT-PCR and virus isolation (Andeweg
et al., 1999) were used to identify enterovirus-positive patients for
this study. For EV68 identiﬁcation and genetic and amino acid sequence
analyses, freshly puriﬁed RNA from stored (−80 °C) enterovirus-
positive clinical specimens was used for partial sequencing of the VP1
gene as described (Nix et al., 2006).Epidemiological analyses GP surveillance data
Patient demographic data, respiratory symptoms and clinical diag-
nosis at the time of GP consultation were used to compare ill persons
infected with EV68 with all other ill persons of whom respiratory
specimens were taken in the same year and week. Data were ana-
lyzed for the period 1996–2010 and separately for the year 2010 be-
cause of the epidemic nature of EV68 detections in 2010.
To compare the course of respiratory disease of EV68-positive and
EV68-negative patients, sentinel GPs were asked to complete a follow-
up questionnaire about the course of disease for 4-weeks following
the onset of disease for patients who were swabbed during weeks
35–40 in 2010, the period of the EV68 epidemic. The questionnaire
addressed the time to recovery of symptoms, repeat consultation and
reasons for repeat consultation, complications, hospitalization, death,
and underlying diseases.
Descriptive analyses were performed to compare demographic
patient characteristics and acute phase and follow-up clinical data.
Differences in proportions were analyzed using Pearson's chi-square
test or Fisher's exact test if ≥50% of the cells have a count less than
5, with p-values≤0.05 considered signiﬁcant. All analyses were per-
formed in SAS software version 9.2 (http://www.sas.com/software/
sas9).
EV68 VP1 sequences
Partial VP1 sequences (nucleotides 132 through 471 relative to the
VP1 gene of the Fermon strain of EV68 [GenBank ID: AY426531],
Table 5
Primers and probes in the 5′ noncoding region used in the nested (1994–2009) and real-time (2009–) RT-PCR protocols.
Speciﬁcity; period in use Primer or probe name; Speciﬁcationa Sequence 5′-3′b Match with EV68b Referencec
Picornavirus speciﬁc
1994–1996 Coxprim 1; OF ACCTTTGTACGCCTGTT 100% 2
Coxprim 2; OR CACGGACACCCAAAGTA 100% 2
Coxprim 3; IF AAGCACTTCTGTTTCCC 1 or 2 mismatches; C or T, C 2
Coxprim 4; IR ATTCAGGGGCCGGAGGA 100% 2
Rhinovirus and enterovirus subset speciﬁc
1996–2009 ncr 1; OF CGGTAAYTTTGTACGCCAGTT 2 or 3 mismatches; C or T, C, T 1
ncr 2; OR ACACGGACACCCAAAGTA 100% 1
ncr 3; IF CAAGCACTTCTGTTTCCCCGG 1 or 2 mismatches; C or T, C 1
ncr 4; IR CATTCAGGGGCCGGAGGA 100% 1
Rhinovirus; P Biotin-AGCCTGCG_TGGCTGCC 1 gap, 2 mismatches; G, G 1
Enterovirus; P Biotin-GGCTGCGTTGGCGGCC 100% 1
Rhinovirus and enterovirus subset speciﬁc
2009– ncr 3; F CAAGCACTTCTGTTTCCCCGG 1 or 2 mismatches; C or T, C 1
ncr 2; R ACACGGACACCCAAAGTA 100% 1
Rhinovirus1; P FAM-TcTTcRcAccCTGT-BBQ 1 mismatch; T This study
Rhinovirus2; P FAM-TcTTSRcAccTTGT-BBQ 100% This study
Rhinovirus3; P FAM-TcTTYRcAccATGT-BBQ 1 mismatch; T This study
2010– Enterovirus; P TXR-CTGCGTTGGCGGCCTRCC-BHQ2 1 mismatch; T This study
Enterovirus speciﬁc
2009– EV-F; F CCCCTGAATGCGGCTAAT 100% 3
EV-R; R CAATTGTCACCATAAGCAGCCA 2 or 3 mismatches; A, A or T, T 3
EV-Pr; P YY-AACACGGACACCCAAAGTAGTCGGT-BHQ1 100% This studyd
a Speciﬁcation: O = outer; I = inner; F = forward; R = reverse; P = probe.
b Positions that mismatch with non coding region sequences from EV68 collected in the time period 1962–2010 (GenBank ID: GU933068–GU933070, GU933077; AY426516–
AY426530; AB569257–AB569276; AB601882–AB601885; EF107098; EU870491; EU870464; AF108187; AY062273–AY062274; AY426531) are underlined and explained in the
“Match with EV68” column. Lower case nucleotide = locked nucleic acid (LNA) nucleotide.
c Reference: 1, Andeweg et al., 1999; 2, Kämmerer et al., 1994; 3, Noordhoek et al., 2008.
d The 3′ end of the original probe described by Noordhoek et al. (2008) was changed from T to G, and GT was added, based on recent available enterovirus 5′ noncoding region
sequences and to accommodate our implementation of the protocol.
56 A. Meijer et al. / Virology 423 (2012) 49–57comprising the putative BC and DE loops of the folded VP1 protein)
from this study are available from GenBank IDs: JF830017–JF830085.
For the evolutionary analyses all EV68 VP1 sequences available
from GenBank by March 31, 2011, with GenBank IDs: AF081348,
AY062278–AY062280, AY42653, AY208116, EF107098, AY355268,
AY426486–AY426500, GQ466485–GQ466487, and AB614406–
AB614444, were included. Data on geographic origin and date of
sampling were retrieved from the GenBank entry or available liter-
ature (Kapikian et al., 1971; Oberste et al., 2004; Savolainen-Kopra
et al., 2009; Schieble et al., 1967). Partial VP1 sequences from 6 pa-
tients hospitalized at the University Medical Center Groningen
(UMCG), Groningen, The Netherlands, of which clinical details have
been published elsewhere (Rahamat-Langendoen et al., 2011), were
kindly provided at the initiation of this study by J.C. Rahamat-
Langendoen and H.G.M. Niesters.
Phylogenetic analysis and evolutionary dynamics
The genetic relationships of EV68 strains was studied using a
Bayesian Markov Chain Monte Carlo (MCMC) approach implemented
in BEAST version 1.5.4 (http://beast.bio.ed.ac.uk) that incorporates
the date of virus sampling (Drummond and Rambaut, 2007). A max-
imum clade credibility (MCC) tree was inferred using partial VP1 se-
quences of Dutch and international EV68 strains, taking into account
the year of specimen collection. The Hasegawa–Kishino–Yano nucle-
otide substitution model with a discrete gamma distribution to ac-
commodate rate variation among sites in the alignment and the
uncorrelated exponential relaxed molecular clock model (Drummond
et al., 2006), selected on the basis of Bayes factor testing (Suchard
et al., 2003), were used for the analysis. Alignment sites were parti-
tioned into ﬁrst plus second codon positions and third codon position
to allow different rates of substitution for these codon positions. The
MCMC analysis was run for 100,000,000 generations and stationarity
and mixing efﬁciency were examined using Tracer software (http://tree.bio.ed.ac.uk/software/tracer). To test the reliability of the tree, pos-
terior probabilities for the branching events were calculated following
removal of the appropriate burn-in.
To infer the population dynamics of EV68 through time, we
employed a Bayesian skyline plot model implemented in BEAST
(Drummond et al., 2005) using the partial VP1 sequences of the
Dutch EV68 strains and the full date of specimen collection.We spec-
iﬁed 20 groups of coalescent intervals to capture the past population
dynamics in the piecewise constant demographic function. The pos-
terior distribution for the Bayesian skyline plot parameters yields the
most plausible piecewise constant expectations for the coalescence
rates through time in the genealogies, which in turn, represent the
most plausible evolutionary histories for the sequence data. The
same settings and run conditions as described above for the tempo-
ral phylogenetic analysis were used. The Bayesian skyline plot was
visualized using Tracer software.
To test the robustness of the model selection on reconstruction
of the phylogenetic tree and the population dynamics, the analyses
were also performed using multiple combinations of nucleotide
substitution and molecular clock models in addition to the optimal
models selected on the basis of Bayes factor testing as described
above.
Amino acid sequence analysis
A phylogenetic tree was inferred from all unique partial EV68 VP1
amino acid signature sequences, determined among all Dutch VP1 se-
quences and international VP1 sequences available in GenBank by
March 31, 2011, by the maximum-likelihood statistical method using
the Nearest-Neighbor-Interchange heuristic method to infer the tree,
substitution model Jones–Taylor–Thornton with gamma distribution
(chosen by best model test), gap treatment by partial deletion with a
cutoff of 95% and 1000 bootstraps to test the phylogeny, using MEGA
5.03 software (http://www.megasoftware.net). Based on the consensus
57A. Meijer et al. / Virology 423 (2012) 49–57bootstrap tree, the amino acid sequence alignment was ordered for
analysis of amino acid variation.
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